前列腺癌碘-125近距离放疗后下尿路症状的变化
本研究纳入706例接受碘-125近距离放疗(BT)的前列腺癌患者,其中265例(38%)联合外照射放疗(EBRT),采用IPSS、IPSS-QOL和OABSS在放疗前及放疗后1至60个月评估下尿路症状(LUTS)。结果显示BT后3个月LUTS最严重但随时间改善,联合EBRT者在24和36个月可出现暂时性储尿症状加重,48个月时与单纯BT者无显著差异。
要点
- BT后3个月总IPSS和OABSS显著升高,分别至36个月和48个月恢复至基线。
- 储尿症状评分在BT后36个月未恢复至基线。
- 联合EBRT者在24和36个月出现暂时性储尿症状加重,48个月时与单纯BT无显著差异。
核心结论
- BT后3个月LUTS包括储尿症状恶化最明显,但随时间改善。
- 接受联合EBRT的患者在BT后24和36个月可能出现尿路症状再次加重。
- 了解BT相关LUTS变化可能影响治疗推荐并帮助患者做出更知情的决策。
研究设计与样本
- 研究纳入706例接受碘-125近距离放疗的前列腺癌患者,其中265例(38%)接受BT联合EBRT。
- 在BT前(基线)及BT后1、3、6、12、24、36、48和60个月记录IPSS、IPSS-QOL和OABSS。
- 储尿症状评分为IPSS问卷中尿频(2)、尿急(4)和夜尿(7)之和,排尿症状评分为排空(1)、间断(3)、弱流(5)和迟疑(6)之和。
主要发现
- 总IPSS在BT后3个月较基线显著升高(平均评分17.1 vs 7.99,P < 0.001),至36个月恢复至基线。
- 储尿症状评分在BT后36个月未恢复至基线。
- 总OABSS在BT后3个月较基线显著升高(平均评分6.52 vs 3.45,P < 0.001),至48个月恢复至基线。
- IPSS-QOL评分在BT后3个月最高(平均评分2.46 vs 3.9,P < 0.001),至48个月恢复至基线,但60个月时低于基线(平均评分2.01 vs 2.46,P < 0.001)。
- BT后1年内LUTS的危险因素为基线IPSS(P < 0.001)和前列腺体积(PV)(P < 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate chronological changes in lower urinary tract symptoms (LUTS) in patients who received iodine-125 brachytherapy (BT) for prostate cancer. METHODS: We enrolled 706 patients who received BT. Of these, 265 (38%) received BT combined with external beam radiation therapy (EBRT). An International Prostate Symptom Score (IPSS), IPSS quality of life (IPSS-QOL) score, and overactive bladder symptom score (OABSS) were recorded before BT (baseline, BL), and 1, 3, 6, 12, 24, 36, 48, and 60 months after BT. The sum of frequency (2), urgency (4) and nocturia (7) of the IPSS questionnaire was defined as the storage symptoms score, whereas the sum of emptying (1), intermittency (3), weak stream (5), and hesitancy (6) was defined as the voiding symptom score. RESULTS: Total IPSS significantly increased at 3 months following BT compared with BL (mean score: 17.1 vs. 7.99, P < 0.001) and returned to BL by 36 months. The storage symptom score did not return to BL 36 months after BT. Total OABSS significantly increased 3 months after BT compared with BL (mean score: 6.52 vs. 3.45, P < 0.001), and returned to BL 48 months after BT. The IPSS-QOL score was the highest score (mean score: 2.46 vs. 3.9, P < 0.001) 3 months after BT and returned to BL 48 months after BT, however the IPSS-QOL score was lower than BL (mean score: 2.01 vs 2.46, P < 0.001) at 60 months. The risk factors for LUTS within 1 year after BT were BL IPSS (P < 0.001) and PV (P < 0.001). Patients who received combined EBRT experienced transient storage symptoms 24 and 36 months after BT, whereas those who received BT alone did not. However, the storage symptom score of the patients who received combined EBRT was improving 48 months after BT and eventually showed no significant difference compared with those treated with BT alone. CONCLUSION: Three months after BT, LUTS, including storage symptoms, deteriorated the most but improved with time. The urinary symptom in patients who received combined EBRT can potentially flare again in 24 and 36 months after BT. Knowledge of changes in LUTS associated with BT may influence treatment recommendations and enable patients to make better-informed decisions.
引用
- Onishi K, Tanaka N, Miyake M, et al. Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. Clin Transl Radiat Oncol. 2018. PMID: 30547097. doi:10.1016/j.ctro.2018.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。